Author Archives: Lu Rahman

#Antibodies #Assay development & optimisation #Bispecific therapeutics

Fast way to screen bispecific antibodies using protein A and His1K biosensors

Recent biotechnological advances have fuelled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for bsAbs… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

Novavax COVID-19 vaccine candidate data at New York Academy of Science

Novavax has announced that Gregory Glenn, President of Research & Development, will present on NVX-CoV2373, the company’s COVID-19 vaccine, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.’ Webinar details are as follows: Presentation title: Efficacy Data Updates from Novavax’ Protein-based Vaccine Candidate Date:  … Read More

#Covid-19 #News

#Gene editing #iPSC #Therapeutics

Horizon applies expertise for iPSC cell line engineering services

The development of therapeutic treatments is a challenging process linked to understanding mechanisms that underly human disorders. Finding the relevant biological model has been a limiting process so far. The development of induced pluripotent stem cell (iPSC) technology has revolutionised the way we study complex disorders. iPSCs offer a unique… Read More

#News

#Immune response #Immunology / Virology & Vaccines

Most immunosuppressed children safe to have vaccines

Both inactivated and live-attenuated vaccines generally produce an adequate immune response and are safe to use in children suffering with autoimmune diseases treated with all but the most potent immunosuppressants, according to a research review. A team from The University of Manchester and Manchester University NHS Foundation Trust examined 37… Read More

#Editor's Choice #News

#Clinical trials #Drug discovery

Clinical trial standard looks to provides global benchmark

GCSA is supporting the UK clinical research industry by providing an internationally-recognised quality benchmark for sites focused on attracting commercial clinical trials to bring the most innovative treatments to patients. Following the rapid approval of COVID-19 vaccines from both Pfizer-BioNTech and Oxford University/AstraZeneca, the UK’s ability to provide a world-leading… Read More

#News

#Covid-19 #Genomics

US professor calls for better genomic monitoring of COVID-19

The emergence of SARS-CoV-2 virus variants highlight the need for better genomic monitoring of the virus, says Katia Koelle, Associate Professor of Biology at Emory University, Atlanta, Georgia. “Improved genomic surveillance of SARS-CoV-2 across states would really help us to better understand how the virus causing the pandemic is evolving… Read More

#Covid-19 #News #Opinion

#Biopharmaceutical #Drug discovery #Ion channels

Metrion Biosciences and Sosei Heptares form strategic drug discovery collaboration

Metrion Biosciences, the specialist ion channel CRO and drug discovery company and Sosei Group, an international biopharmaceutical group, will apply Sosei Heptares’ structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration. Ion channels are a class of integral membrane proteins… Read More

#News

#Cell therapy #Immunology

Lonza releases cryopreserved leukopaks for immunology and cell therapy research

Lonza has launched fully customisable, cryopreserved Leukopaks. The frozen Leukopaks will enable long-distance shipping of leukapheresis products without the concern of reduced cell viability encountered with fresh Leukopaks. Being suitable for long-term storage in research labs, the cryopreserved Leukopaks will also allow immediate access to viable cells for greater convenience… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

Janssen COVID-19 vaccine: 66% efficacy in one shot

An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase III clinical data. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax COVID-19 vaccine demonstrates 89.3% efficacy

Novavax, the biotechnology company developing next-generation vaccines for serious infectious diseases, has announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase III clinical trial conducted in the UK. The study assessed efficacy during a period with high transmission… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #CRISPR #Diagnostics

Mammoth Biosciences and Agilent partner on CRISPR-based SARS-CoV-2 diagnostic

Mammoth Biosciences has announced an agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution comprising Agilent’s Bravo automation workstation and Mammoth Biosciences’ DETECTR BOOSTTM assay. Together, the DETECTR BOOSTTM SARS-CoV-2 kit and Agilent automated liquid handling system would provide a complete workflow for… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics

Using digital technology to solve compound management problems

Managing Director of Ziath, Neil Benn MSc, explains to Lu Rahman how the latest mobile and internet-enabled technologies will impact the science of compound management. Ziath is a UK-based company specialising in design, development and production of instrumentation for sample management. Ziath’s primary product range is 2D barcode scanners for… Read More

#Exclusive Content

#Cell culture #Drug discovery #Organ-on-a-chip

Sitting down with…CN Bio

CN Bio is a cell culture company whose mission is to transform the way human-relevant pre-clinical data is generated by developing the most complete model of the human ‘body-on-a-chip’ in the laboratory.  Achieving this is what drives the company’s future initiatives, CEO Dr David Hughes told Lu Rahman. CN Bio… Read More

#Editor's Choice #Exclusive Content #News #Opinion